Kaiser Zepbound Prior Authorization: The 2026 Rules, by Region

Affiliate disclosure: Some links on this page are affiliate links. If you start a program through one, we may earn a commission at no extra cost to you. Affiliate money did not decide which Kaiser documents we opened, what those documents say, or what we recommend below. Where a free path beats a paid one, we say so.

This page explains public plan documents. It is not medical advice, and it cannot promise coverage. Your own Evidence of Coverage and Kaiser's written decision are what actually control your case.

The RX Index is not affiliated with or endorsed by Kaiser Permanente, Eli Lilly, CMS, Medicare, or the California Department of Managed Health Care.

Kaiser Zepbound prior authorization isn't one national form. And here's the part almost nobody explains: two completely separate things decide your answer, and only one of them has anything to do with your health.

The first is whether your plan buys weight-loss drugs at all. Some Kaiser plans don't. If yours doesn't, no form fixes that.

The second is whether you meet Kaiser's medical rules — and those change depending on where you live. In Kaiser Northwest, if none of the required trials is already documented and the trials happen one after another, the stated minimums add up to about a year: two older weight-drug trials at three months each, then at least six months of semaglutide, followed by bariatric medicine chart review.

California is a different animal entirely. Kaiser's current California Commercial HMO formulary says, in writing, that the plan doesn't require prior authorization or step therapy. But Zepbound isn't listed in that formulary, so the practical route is a non-formulary coverage determination — not automatic coverage.

So "Kaiser Zepbound prior authorization" isn't one rule. It's at least nine public plan paths wearing the same name. We opened Kaiser's actual criteria and formulary documents — Northwest, Georgia, Mid-Atlantic, California, Hawaii, Colorado, Washington, and more — to find out which one applies to you.

Below: the exact criteria by region and plan type, the sleep apnea numbers that change the answer, the four kinds of "no" and what each one really means, the current California appeal rules, and what Zepbound costs if the answer stays no.

Jump to: benefit check · rules by region · step requirements · sleep apnea · California · denials · appeals · cost · renewals · FAQ

Is this page for you?

Yes, if:

• You have Kaiser and your doctor mentioned "getting it approved"
• Your Zepbound request was denied and you don't know why
• The pharmacy quoted you a price that made your stomach drop
• You're about to switch to Kaiser and you're already on Zepbound
• Your approval is expiring and you're worried about the renewal

No, if:

• You have type 2 diabetes and you're asking about Mounjaro. Kaiser treats that as a totally separate lane with its own rules. Go here instead: Kaiser Mounjaro prior authorization.
• You're shopping for compounded tirzepatide. This page is about FDA-approved Zepbound and insurance. Compounded products are a different category, are not FDA-approved finished drugs, and we don't treat them as interchangeable with Zepbound.

Kaiser Northwest's current Zepbound PDF also contains a separate section labeled for type 2 diabetes. Zepbound itself is not FDA-approved as a diabetes treatment; Mounjaro is the tirzepatide product approved for type 2 diabetes. This page covers Zepbound's FDA-approved uses: chronic weight management and obstructive sleep apnea.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

The right GLP-1 provider isn't the same for everyone — it depends on your state, your insurance and formulary, whether you want an FDA-approved or compounded medication, your preferred treatment path (injection or oral), and your budget. Because a general answer can't resolve those for you, use The RX Index's Find My GLP-1 Path tool to get a personalized provider match with source-verified pricing before you choose.

What we actually verified

We don't publish a rule unless we opened the document it came from. Here's exactly what we read, and — just as important — what these documents can't tell you.

Documents and pages checked on August 8, 2026:

What none of these documents can tell you: whether your specific employer or plan sponsor bought the weight-loss drug benefit. That isn't settled by a general formulary. It's in your Evidence of Coverage, Summary Plan Description, rider, or other plan document, and for many Kaiser members it's the first fact that decides everything. We show you how to find it in about five minutes below.

What we did not verify, and won't pretend to: Kaiser's Zepbound approval rate, its denial rate, or one average Kaiser-wide decision time. You'll see precise-looking percentages floating around on other sites. We could not find a reliable national Kaiser source for any of them. We'd rather leave a hole than fill it with a made-up number.

Kaiser Zepbound prior authorization: does every plan require it?

Sometimes — but there is no single national Kaiser rule, and “prior authorization” is often the wrong term for what's actually happening. Kaiser Northwest treats Zepbound as non-formulary and runs a clinical review. Kaiser Mid-Atlantic uses a formal PA form. Kaiser Georgia publishes detailed review criteria. Kaiser's California Commercial HMO formulary states that the plan “does not have a requirement for PA” or step therapy and uses a coverage-determination process for non-formulary drugs instead.

That's four different machines with four different sets of levers. Same company. Same drug.

This matters more than it sounds. If you have a California Commercial HMO and ask only for “the Zepbound prior authorization form,” you may be asking for the wrong document. Ask whether the drug is non-formulary and whether your prescriber needs to submit a supporting statement for a coverage determination.

The four kinds of “no” — and why the difference decides everything

Almost every Kaiser Zepbound problem is one of these four. They look identical from the outside. They're solved in completely different ways.

Read that last row twice. It's where most people lose months.

If your plan excludes weight-loss medications as a category, you can have a BMI of 42, three qualifying conditions, and a five-page letter from your doctor — and still get a no. Not because you failed a medical test. Because the plan doesn't include that benefit.

We've seen people fight the wrong battle for half a year over this. Which brings us to the first thing you should do.

First question: does your Kaiser plan buy weight-loss drugs at all?

Before Kaiser looks at your BMI, it checks whether your plan covers weight-loss medications as a category. Kaiser Northwest's Zepbound criteria document opens by stating the drug is covered for weight loss “only for Kaiser Northwest members with coverage for medications used to treat weight loss,” and that everyone else pays the member cash price. Meet every clinical rule perfectly and you can still be denied on this alone.

Here's the confusing part: two different departments may be answering two different questions.

A formulary is a list of drugs the plan might pay for. A benefit is whether the plan includes that category under your exact coverage.

Picture two people. Same city. Both have Kaiser. Both have a BMI of 34 and high blood pressure. Both have supportive doctors. One gets approved. One gets told weight-loss drugs aren't covered.

Nothing about their bodies is different. Their plan documents are.

How to find out in five minutes

Option 1 — Look it up yourself. Log into kp.org, open your Evidence of Coverage, Summary Plan Description, Certificate, or drug-benefit rider, and search the document for “weight,” “obesity,” “anti-obesity,” and “weight management.” You're looking for either a covered category or an exclusion list.

Option 2 — Call and ask the right question. This is the part that matters. Most people call and ask “Is Zepbound covered?” and get a formulary answer to a benefit question. Then they hang up believing they have an answer they don't have.

Say this instead:

“I need to know two separate things. First: does my prescription drug benefit include medications for weight loss as a covered category? That's the benefit itself, not a specific drug. Second: is Zepbound on my exact plan's formulary, or would it need prior authorization, clinical review, or a non-formulary coverage determination? Which dosage form is preferred? Can you also tell me which section of my Evidence of Coverage covers this?”

Naming the difference out loud is what gets you the real answer. Write down who you spoke to and when.

Option 3 — If your coverage came through work, ask your HR or benefits administrator whether the plan includes a weight-management drug rider. Kaiser Member Services can tell you what your current plan says. Your employer or plan sponsor can explain what it selected and whether another option may be available at renewal.

### Before you pay cash, make the free call Five minutes. No email. No signup. Confirm the benefit, the formulary status, the dosage form, and the review path first. If Kaiser still isn't a workable route, use The RX Index's Find My GLP-1 Path tool to compare outside options with current pricing.

Which Kaiser rule applies to my plan?

Four facts decide your path: your Kaiser region, your exact plan type, whether your plan includes the relevant drug benefit, and whether Zepbound is being requested for weight management or obstructive sleep apnea. The same state can have different answers under a Kaiser pharmacy plan and a KPIC plan.

That last sentence is not a technicality. Hawaii proves it, and we'll show you in a minute.

What to grab before you call anyone

Have these in front of you:

• Your Kaiser region (Northwest, Southern California, Northern California, Colorado, Georgia, Hawaii, Mid-Atlantic, Washington)
• Your full plan name as printed on your card — not just “Kaiser”
• Your plan type: HMO, PPO, POS, or KPIC
• Where the plan came from: employer, bought it yourself, Covered California or another marketplace, Medicare, Medicaid, FEHB (federal), or PSHB (postal)
• Your group number, if there is one
• Your current Evidence of Coverage

The plan type is the one people skip, and it's the one that changes the answer most often.

The Kaiser Zepbound Rule Register (2026)

This is the table we built this page around. Every row traces to a Kaiser document with a date on it, and every row carries an honesty label so you can see how complete the public evidence actually is.

What the labels mean:

• Full published criteria — Kaiser publishes the complete clinical checklist. You can read exactly what you have to prove.
• PA form published — Kaiser publishes an actual form with the questions on it.
• Formulary flag only — the drug list shows a restriction like PA, tier, quantity limit, or mail-order status, but the full clinical reasoning isn't published there.
• Process described only — Kaiser explains how requests work but doesn't publish drug-specific criteria on that page.
• Your plan documents decide — the public sources genuinely don't settle your individual benefit or cost. Your Evidence of Coverage does.

A “formulary flag only” or “process described only” label does not mean you're not covered. It means Kaiser didn't publish the whole answer there. Sites that quietly fill those gaps with guesses are how bad advice spreads.

FEHB note: the Mid-Atlantic form above explicitly covers FEHB. FEHB members in other Kaiser markets should use the formulary and Evidence of Coverage for their own market instead of borrowing the Mid-Atlantic rule.

Look at Hawaii again

Same state. Same company. Two plan paths.

The public Hawaii Kaiser pharmacy page says no drugs currently require formal PA at Kaiser pharmacies and points members to a non-formulary exception when needed. The Hawaii KPIC Added Choice formulary lists Zepbound with a PA flag and a quantity limit.

If you searched “Kaiser Hawaii Zepbound prior authorization” and landed on an article that gave one answer for every Hawaii member, that answer was too broad.

This is why we keep hammering plan type. The state name on your card isn't enough.

What Kaiser makes you try first — and how long that really takes

There is no Kaiser-wide step ladder. Kaiser Northwest's published criteria can add up to twelve months of stated minimum trial time when the trials happen one after another and none already count. The current Mid-Atlantic form uses a BMI-based ladder and requires three months of semaglutide for every weight-management BMI group. Georgia requires you to clear at least two oral options and then at least four months of semaglutide through documented failure, intolerance, or contraindication.

This is the section that actually tells you when you can start.

The Northwest ladder, step by step

Step 1 — Fail any two of these five. Each failed trial must last three months under Kaiser's definition of an “adequate trial.” The alternate route is narrower than it sounds: to skip the oral ladder entirely, the document requires an allergy, intolerance, or contraindication to all five listed therapies.

• phentermine
• diethylpropion
• topiramate
• Qsymia (phentermine plus topiramate)
• Contrave (naltrexone plus bupropion)

Step 2 — Fail semaglutide, or document a semaglutide allergy, intolerance, or contraindication. The trial is Ozempic or Wegovy for at least six months.

Step 3 — Bariatric medicine reviews your chart and decides whether switching you to tirzepatide is warranted.

Step 4 — Now your Zepbound request gets looked at.

Three months, plus three months, plus six months. That's twelve months if the trials happen one after another and none already count. Before step four.

We're not telling you this to discourage you. We're telling you because if you're starting from zero in the Northwest, “I'll ask my doctor and see what happens” is not a plan — and knowing the shape of the year ahead changes what you ask for at your very next appointment.

The Mid-Atlantic ladder now changes by BMI

The current Commercial, Exchange, and FEHB form, effective August 4, 2026, uses four BMI lanes:

Every weight-management lane also asks for a baseline weight from the past 30 days, no concurrent GLP-1 or GIP/GLP-1 drug, the required referral or specialist path, and documented intolerance, contraindication, or failure to lose and maintain at least 5% after a three-month trial of semaglutide at the maximum tolerated dose.

The form lists Zepbound KwikPen as preferred. Zepbound single-dose products are listed as nonpreferred. That dosage-form detail can decide whether a claim clears even after the medical rules do.

Georgia uses a higher entry bar and office-only weights

Georgia's current non-Medicare criteria are not a blank anymore. They require:

• A verified Class III obesity rider
• A starting weight measured in the office within one month; remote patient-reported weight isn't accepted
• Age 18 or older
• An eligible Kaiser-affiliated endocrinology, weight-management, adult-medicine, or family-medicine prescriber
• BMI 40 or higher, or BMI 35 or higher with a listed condition
• At least two listed oral options cleared by a three-month failure to lose and maintain 5%, a contraindication, or an intolerance
• At least four months of high-dose or maximum-tolerated semaglutide, unless a contraindication or intolerance clears that step
• No current use of another GLP-1, GIP/GLP-1, or DPP-4 drug

Georgia's preferred form is also Zepbound KwikPen. Initial approval is six months. The first continuation is six months. Later approvals can run twelve months. The office-measured weight-loss test is at least 8% by six months or 15% by twelve months.

The real ways around a required drug — and their catch

A documented allergy, contraindication, or intolerance can replace a trial only where the plan's rule says it can. In Northwest, the oral-ladder exception is written as an exception to all five listed oral therapies. Semaglutide has its own separate exception.

Here's the catch, straight out of Kaiser Northwest's own document. Intolerance “excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation.”

In plain English: mild, expected nausea that settles down and doesn't make you stop the drug may not count. A reaction that forced you to stop is a different record.

What counts as proof (this is where good cases die)

“The patient tried other weight-loss medications” is not documentation. It's a sentence. Kaiser's reviewers need specifics.

If you've tried any of these before — even years ago — bring the details to your appointment and ask your doctor to put them in the chart. A memory is not a medical record. This is the single highest-leverage thing you can do today.

Fill one row per drug. Take it with you.

### Build the medical-necessity file your doctor needs The live guide shows the six evidence points insurers keep asking for, what to attach, and when a letter cannot fix the denial. Free, no email required. → Open the GLP-1 medical-necessity checklist

If you're switching to Kaiser Northwest and already take Zepbound, read this twice

Buried in Kaiser Northwest's criteria is a separate section for new members who are already taking the medication.

For chronic weight management or sleep apnea, those members need two things in the public criteria: a prescription drug benefit that covers weight-loss medications, and current Zepbound use for one of those conditions.

No two-of-five. No six months of semaglutide. No bariatric chart review. The published approval period is twelve months.

If you're on Zepbound now and about to move to Kaiser at open enrollment, that paragraph is worth more to you than anything else on this page. Three practical notes:

1. Bring proof that you're actively taking it: current prescription, dose, start date, and recent fill history.
2. Bring your starting weight and current weight. Don't make the new office rebuild the history from memory.
3. Ask how any treatment gap would affect classification. The public Northwest criteria don't state a maximum allowed gap.

Does the sleep apnea route work at Kaiser?

Zepbound is FDA-approved for adults with obesity and moderate-to-severe obstructive sleep apnea. The clinical program defines moderate-to-severe OSA as an apnea-hypopnea index of 15 or more events per hour. Kaiser Northwest's published criteria require severe sleep apnea — an AHI of 30 or higher — and apply the same full step-therapy ladder as the weight-loss route. At Kaiser Northwest, sleep apnea is a narrower door, not a wider one.

The FDA approval opened a separate OSA route. At Kaiser Northwest, that route is still strict.

(Quick definition: the apnea-hypopnea index, or AHI, is how many times per hour your breathing stops or gets shallow while you sleep. 5 to 14 is mild. 15 to 29 is moderate. 30 and up is severe.)

Kaiser Northwest's bar is double the FDA study threshold

If your AHI is 22 and you otherwise meet the FDA-labeled OSA population, you are inside the FDA-approved use — and outside what Kaiser Northwest's published OSA criteria will pay for.

A plan can use coverage criteria that are narrower than the FDA indication. That's exactly what the Northwest document does here.

Kaiser's own Mid-Atlantic forms disagree with each other

The current Mid-Atlantic Commercial, Exchange, and FEHB form is stricter than Northwest on BMI. It requires:

• Severe OSA with AHI 30 or higher on a sleep study from the past year
• BMI 50 or higher
• PAP intolerance or inability confirmed by a sleep specialist, or residual AHI 5 or higher despite compliant PAP use
• A referral through the injectable-weight-loss review path, or prescribing by a pulmonologist or weight-management specialist
• 90 days of documented lifestyle work
• No diabetes, central or mixed apnea, bariatric surgery, or several other listed exclusions

But the separate Maryland HealthChoice form asks for moderate-to-severe OSA with AHI 15 or higher, BMI 30 or higher, no diabetes, and an OSA-experienced clinician.

So: one Mid-Atlantic form matches the FDA threshold. Another requires AHI 30 and BMI 50.

There is no such thing as “the Kaiser sleep apnea rule.” There is only your plan's rule.

Who should stop reading this section right now

• Moderate OSA (AHI 15–29) with a Kaiser Northwest plan? This route isn't yours under the public criteria. Look at the weight-management route if you have the benefit, or the cash paths further down.
• Sleep apnea and type 2 diabetes? Northwest and both Mid-Atlantic OSA forms reviewed here exclude that OSA lane. Tirzepatide for diabetes is a different conversation with different rules — start at Kaiser Mounjaro prior authorization.
• Central, complex, or mixed sleep apnea? Northwest excludes central or complex apnea. The current Mid-Atlantic Commercial, Exchange, and FEHB form excludes central or mixed apnea.

One thing worth saying plainly: do not change the condition on your request to get around a rule. The diagnosis has to be your actual diagnosis. A request that doesn't match your chart can be denied for missing or inconsistent information — and now you've burned a cycle.

Why California Commercial HMO works completely differently

Kaiser's 2026 California Commercial HMO Formulary states in its own definitions that Kaiser Foundation Health Plan “does not have a requirement for PA” and “does not have a requirement for Step Therapy.” In this plan, a drug that isn't on the formulary goes through a coverage determination. The formulary sets the clock at 72 hours for a standard decision and 24 hours for an urgent one.

We went looking for California's Zepbound prior authorization criteria and found something better: a current Commercial HMO formulary that says the process you're searching for isn't the process that plan uses.

Here's what happens instead.

A coverage determination still needs a medical case

The member, an appointed representative, a Kaiser or affiliated doctor, or another prescriber can request a coverage determination. The medical part still depends on the prescriber explaining why the non-formulary drug is necessary.

If Kaiser approves the request, the formulary says the drug is covered under the plan's benefit terms, as long as you have a prescription drug benefit. If you don't, you pay full retail.

There's that benefit gate again. It never goes away.

The 72-hour clock, and the trick to it

Kaiser's California Commercial HMO formulary is unusually specific: 72 hours for a standard decision, 24 hours for an urgent one.

But read the fine print. The clock starts when the prescriber submits the supporting statement — not when you asked for it.

This is why a request can feel slow before the formal clock has even started. Ask this, in these words:

“Has the supporting statement been submitted? What date did it go in, and is there a reference number?”

If it's approved on a standard request, the formulary says the exception covers the drug for the duration of the prescription, refills included. On an urgent request, it covers the duration of the urgency.

If your doctor doesn't think the drug is medically necessary and you disagree, that's a grievance, not an exception. California Member Services: 1-800-464-4000.

One correction while we're here

Kaiser's California Commercial HMO formulary uses Tier 1, Tier 2, and Tier 4. There is no Tier 3.

If you've read that Zepbound or Mounjaro is “Tier 3 in Kaiser California,” that tier doesn't exist in this document. It's a small thing. It's also a reliable tell that a page was written without opening the formulary.

We searched the complete current formulary

We searched the full 152-page California Commercial HMO formulary effective August 4, 2026 for both “Zepbound” and “tirzepatide.” Neither appears.

That means Zepbound is non-formulary under this specific Commercial HMO document. It does not prove that every Northern California, Marketplace, Medicare, Medi-Cal, employer, or KPIC plan uses the same list.

Check your own document: go to Kaiser's formulary page, choose the exact California plan printed on your card, and search the PDF for “Zepbound” and “tirzepatide.” Two minutes, and you'll know more about your own plan than a state-wide answer can tell you.

How long does this actually take?

There are two clocks and people constantly confuse them. The decision clock can be short — California Commercial HMO publishes 72 hours for a standard coverage determination and 24 hours for an urgent one. The eligibility clock is the long one: if you haven't yet completed or medically cleared the medications your plan requires, that can mean months of documented trials before a request is ready.

When someone says “Kaiser is taking forever,” it may be the second clock.

The decision clock is how long Kaiser takes to answer a request that's already complete and filed. California Commercial HMO publishes 72 and 24 hours, starting when the prescriber supplies the supporting statement. The public documents reviewed for the other rows don't give one shared Kaiser-wide number, so ask for the expected window when the request goes in and write down the reference number.

The eligibility clock is how long until your record clears the rule. In Northwest, starting from zero with sequential trials, the stated minimums add up to about a year. Georgia asks you to clear at least two oral options through three-month failures or medical exceptions, then clear at least four months of semaglutide. Current Mid-Atlantic uses 90 days of lifestyle work for BMI below 40, an oral step for BMI below 35, and three months of semaglutide for every weight-management BMI group.

Five legitimate ways to move faster

None of these involve claiming anything untrue.

1. Get your past attempts into the chart. If you tried phentermine in 2022, it may count if the plan accepts it — but only if it's documented with dates, dose, outcome, and a reason you stopped. Tell your doctor explicitly.
2. Ask for a current weight and BMI at this visit. Northwest and Mid-Atlantic want measurements from roughly the last 30 days.
3. Ask whether an active behavioral-health referral satisfies Northwest's lifestyle requirement. The Northwest document accepts an active referral, not just a completed program.
4. Make sure a real intolerance is written as one. If a drug made you sick enough to stop, the chart should say that, in those terms.
5. Use the right kind of weight. Georgia requires an office measurement and says remote patient-reported weight isn't accepted.

Why was my Zepbound request denied?

A denial can mean four very different things: your plan excludes the drug category, Zepbound or the requested dosage form is non-formulary, you didn't meet the clinical criteria, or information was missing. The written language in the denial — not the word “denied” — determines whether the right next move is a correction, a coverage determination, a formulary exception, or an appeal.

Get the decision in writing before you do anything else. Then find your row.

“Not covered” is not a reason

If your denial says nothing more than “not covered,” call and ask for six specific things:

1. The written decision
2. The specific reason or denial code
3. Which criteria, policy, formulary, and dosage-form rule they applied, with the effective date
4. Exactly what was missing or not met
5. Whether the next step is correction, coverage determination, formulary exception, or appeal
6. Your deadline, and where to send it

Everything downstream depends on getting that list.

How do I appeal a Kaiser Zepbound denial?

Which appeal works depends entirely on why you were denied. If Kaiser said the drug isn't medically necessary for you, that medical decision may qualify for an outside Independent Medical Review. If Kaiser said your plan doesn't cover weight-loss drugs, that's a benefit dispute. If your California plan is regulated by DMHC, the department decides whether the case belongs in IMR or its consumer-complaint process. Same word, “denied.” Two different doors.

This distinction is one of the most useful things on this page.

If your California plan is regulated by DMHC and the denial is medical

Start with a grievance through Kaiser. The current DMHC form says the plan generally must give a decision within 30 days, or within 3 days if the problem is an immediate and serious threat to your health. If the issue is urgent, contact the DMHC Help Center immediately; its current instructions say urgent members may file directly instead of waiting through the ordinary grievance clock.

Then comes the Independent Medical Review through California's Department of Managed Health Care. It's free. Independent reviewers decide the medical issue. The plan has to follow the result.

And it works more often than people expect. The current DMHC form says approximately 73% of patients receive the requested service through IMR.

You'll see “60%” or “72%” quoted on other sites. The current 73% figure comes from the state form that members use to file.

The deadlines and clocks that matter:

• 6 months after the plan sends its written appeal response to apply for IMR; DMHC may accept a late request when circumstances prevented timely filing
• 45 days is the usual overall IMR timeframe printed on the current form
• 7 days for an urgent IMR
• 5 working days for the plan to authorize the service after a favorable IMR decision is adopted

DMHC Help Center: 1-888-466-2219. Filing is free. Your denial notice or Evidence of Coverage should name the regulator. If DMHC doesn't regulate your plan, its Help Center can route you to the right agency.

If you were denied because your plan excludes weight-loss drugs

Here's the hard part. A benefit exclusion is not the same as a medical-necessity denial.

IMR reviews a medical decision. It doesn't rewrite the plan contract. DMHC can still review a coverage dispute through its complaint process, and the current combined form tells DMHC to decide which process applies.

Use the same DMHC IMR/Complaint form and describe the issue exactly. Don't relabel a clear benefit exclusion as a missing chart note.

Be realistic with yourself: the practical fix for a true, clearly written benefit exclusion is often open enrollment, an employer or plan-sponsor rider, a different plan, a separate covered indication that genuinely applies, or a cash path. Not a stronger BMI paragraph.

Ask whether a clinician-to-clinician review is available

Before you file anything formal, ask whether your Kaiser clinician can request a peer-to-peer or other direct review with the reviewing clinician.

That can be worth trying when the dispute is missing or unclear documentation. It doesn't create a benefit the plan excludes.

Outside California

Most plan types provide an internal appeal and may provide external review, but deadlines and eligibility depend on your plan and denial type. Use the date, deadline, address, and process printed on your denial notice. There is no universal Kaiser deadline.

### Get the appeal packet that matches the actual denial The free tool builds a patient cover letter, criteria request, clinician-record request, attachment list, and deadline tracker without inventing medical facts. → Open the GLP-1 appeal-letter builder

What if my Kaiser plan excludes weight-loss drugs entirely?

A standard prior authorization usually cannot create a benefit your plan doesn't include. Before you spend months on a clinical appeal, confirm in writing that this is a true category exclusion and not a non-formulary, dosage-form, or criteria denial. If it is a real exclusion, your realistic options are a plan-sponsor rider, a separate coverage pathway if one medically applies, a different plan at open enrollment, or a cash-pay path.

Ask Kaiser for these in writing:

• Which section of the Evidence of Coverage, Summary Plan Description, or Certificate contains the exclusion
• Whether it excludes the specific drug, the weight-management indication, or all anti-obesity medications
• Whether the plan has a rider, supplemental benefit, or exception process
• Whether another FDA-approved indication is handled separately when it genuinely applies
• Whether the employer or plan sponsor offers another plan option at renewal

Then ask your employer's benefits team the rider question directly. Kaiser can tell you what your plan says today. Your employer or plan sponsor can explain what it selected and what may be available at the next renewal.

How much does Zepbound cost with Kaiser — and without it?

There is no single Kaiser Zepbound price. What you pay depends on whether it's covered, the dosage form and tier, your deductible, whether you owe a flat copay or a percentage, and which pharmacy fills it. An approved request answers whether your plan will pay something — not whether your share will be small.

That gap surprises people constantly. Approval and affordability are two separate questions.

Why an approved request can still show a scary price

• Your deductible isn't met yet
• You owe coinsurance (a percentage) rather than a flat copay
• The drug sits on a high-cost tier
• The claim went through the wrong pharmacy channel or dosage form
• The approval hasn't been attached to the claim yet
• The fill exceeds a quantity limit

Ask the pharmacy for the exact rejection message or code. “It's not going through” isn't diagnosable. A code is.

The honest cost paths, with coverage before cash

We're going to put our affiliate offer last on this list, because that's where it honestly belongs.

Prices and program terms verified August 8, 2026. Manufacturer and provider terms can change. Check the price before paying.

If you have Medicare Part D, look at that second row hard — but don't assume Part D alone qualifies you. The Bridge is a nationwide CMS program through December 31, 2027, for weight management only. CMS tests the age, BMI, and health criteria at the time GLP-1 treatment started: age 18+ with BMI 35+; BMI 30+ with heart failure with preserved ejection fraction, uncontrolled high blood pressure despite two medicines, or stage 3a or worse chronic kidney disease; or BMI 27+ with prediabetes, a prior heart attack, a prior stroke, or symptomatic peripheral artery disease. A Zepbound prescription for moderate-to-severe OSA stays in the ordinary Part D lane, not the Bridge. CMS also says a beneficiary who received a GLP-1 through Part D during calendar year 2026 is not eligible for the Bridge in 2026. Start here: Medicare GLP-1 Bridge program.

Want the real monthly total, not just the medication price? Use the GLP-1 cost calculator to add membership, medication, visits, supplies, and insurance cost-sharing.

If Kaiser says no and you need a path this month

Let's be direct about who this section is for. It's for the reader who has confirmed their plan won't pay, or who has looked at the real ladder and decided that isn't going to work for them.

If that's not you yet — go back up and make the phone call first. It's free and it might save you hundreds a month.

The part we'd rather not tell you about Ro

Ro is not the clean route for making a Kaiser HMO pay.

Kaiser Northwest uses an internal clinical-review path. Georgia requires a Kaiser-affiliated prescriber. Mid-Atlantic names a referral or specialist lane. Ro says its insurance concierge handles prior authorization generally, but that doesn't turn an outside telehealth prescriber into the Kaiser clinician or internal pathway a specific Kaiser rule may require.

So if your goal is to have Kaiser cover Zepbound, start with the Kaiser route. It's the route that directly tests the Kaiser benefit and criteria described on this page. Jump back to the region table.

Now the flip side — and it's the whole reason Ro is on this page.

If you choose Ro's cash-pay path, Kaiser's benefit exclusion, step ladder, and authorization system don't decide the purchase. A Ro clinician still has to review your health history and decide whether treatment is appropriate. But you aren't asking Kaiser to pay, so the Kaiser coverage rules aren't the gate.

That's not a loophole. It's just what buying a medication with cash looks like instead of asking a plan to pay for it.

What Ro actually is: a telehealth weight-management program with licensed clinicians, ongoing support, and access to FDA-approved branded GLP-1 medications when prescribed. Ro Body membership is $39 for the first month, then $149/month, or as low as $74/month with an annual plan paid upfront. Medication is billed separately. Add both together before comparing it to anything else.

Where Ro is weaker: the membership cost sits on top of the drug price, and it isn't a substitute for Kaiser's internal care path. No telehealth intake guarantees that a clinician will prescribe Zepbound.

And the thing we're not supposed to say: if you already have a clinician willing to write the prescription, LillyDirect has the lower published base total in the comparison above because you aren't adding a Ro membership to the medication price. We earn nothing when you do that. We're telling you anyway, because a page that hides it isn't worth trusting on anything else.

### Does that sound like your situation? → Check Zepbound eligibility and current pricing on Ro (affiliate link, opens in a new tab) The eligibility check doesn't guarantee a prescription. Review the membership and medication total before paying.

For more outside-Kaiser choices and the exact limits of each route, see GLP-1 providers that accept Kaiser members.

How do Zepbound renewals work at Kaiser?

Renewal is a separate evidence event, not an automatic extension. The test changes by plan: Kaiser Northwest looks for at least 5% loss achieved and maintained; Georgia requires 8% by six months or 15% by twelve months using office weights; Mid-Atlantic weight-management renewal looks for 5% loss in the previous three months; its Commercial, Exchange, and FEHB OSA renewal looks for at least 25% AHI improvement.

A renewal can fail even when the medication helped if the plan can't see the correct starting number, current number, or time window.

Notice the Northwest wording: “achieved and maintained.” Losing 8% and drifting back to 3% can fail a renewal that a steady 6% would pass.

Write these six things down today, wherever you keep important stuff:

1. Your exact baseline weight
2. The date, location, and method of that measurement
3. Your BMI at baseline
4. Your baseline AHI, if the request is for OSA
5. Your authorization start date
6. Your authorization end date

Then book your renewal visit before that end date, not after. Give the office time to get the accepted measurements, collect the records, and submit the request.

What to say to Kaiser, your pharmacy, and your doctor

Scripts beat improvising. Copy these.

To Member Services:

“I'm checking Zepbound coverage under my exact plan for [weight management / obstructive sleep apnea]. Does my plan include the relevant drug benefit? Is Zepbound on this exact plan's formulary, and does the plan use formal prior authorization, clinical review, or a non-formulary coverage determination? Which Zepbound dosage form is preferred? Can you give me the current policy or form name with its effective date, and the Evidence of Coverage section that applies?”

To the pharmacy:

“Can you read me the exact rejection message or code on this Zepbound claim? I'm trying to tell whether this is prior authorization, non-formulary status, a benefit exclusion, a quantity limit, a nonpreferred dosage form, a pharmacy-channel issue, or just the price after approval.”

To your clinician:

“Can we compare my records against Kaiser's current criteria for my region and exact plan? I want to make sure the request has a recent accepted weight and BMI, the right diagnosis, my qualifying conditions, my lifestyle history, and the specific drugs I've already tried — with dates, doses, outcomes, and why I stopped each one. Can you also confirm that we're requesting the preferred Zepbound form and using the required referral or prescriber path?”

After a denial:

“Please tell me exactly which requirement wasn't met, what information was missing, which criteria, policy, or formulary you applied and its date, and whether my next step is a correction, coverage determination, formulary exception, or appeal.”

Why Kaiser Zepbound coverage feels impossible to decode

The confusion is structural. Kaiser publishes different rules by region, plan type, program, and dosage form.

The current public evidence shows:

• Northwest publishes a complete clinical ladder.
• Mid-Atlantic publishes different forms for Commercial, Exchange, and FEHB plans and Maryland HealthChoice.
• Georgia publishes exact BMI, prescriber, trial, and renewal thresholds.
• California Commercial HMO says no PA or step therapy but leaves Zepbound off the formulary.
• Hawaii's Kaiser pharmacy page says no drugs currently require PA, while Hawaii KPIC puts a PA flag directly on Zepbound.
• Colorado KPIC and Washington PSHB publish tier and restriction flags without the full clinical test in the formulary row.

That's why someone else's approval doesn't settle your plan, and someone else's denial doesn't mean yours is hopeless. We don't publish anonymous success stories as proof of anything, and we won't attach a star rating to an insurance process.

If you feel like you're the only one who can't get a straight answer, you aren't. The confusion is structural. The internet keeps flattening several real Kaiser systems into one imaginary national policy.

That's the actual problem this page exists to solve.

Before you request: what to know about Zepbound itself

Getting a request approved is not the same as the medication being right for you. Zepbound's current FDA labeling includes a boxed warning about thyroid C-cell tumors, specific contraindications, pregnancy-related warnings, and other serious warnings and precautions. Only a licensed clinician who knows your history can decide whether it's appropriate.

Briefly, from the FDA-approved labeling revised April 2026:

• Zepbound is FDA-approved for chronic weight management in eligible adults, and for moderate-to-severe obstructive sleep apnea in adults with obesity.
• It carries a boxed warning related to thyroid C-cell tumors. It shouldn't be used by people with a personal or family history of medullary thyroid carcinoma, or with Multiple Endocrine Neoplasia syndrome type 2.
• It shouldn't be used with another tirzepatide product, and combining it with another GLP-1 receptor agonist isn't recommended.
• Zepbound may cause fetal harm. The label says to stop it when pregnancy is recognized and to discuss pregnancy plans with the prescriber.
• Read the Medication Guide and full prescribing information, and tell your prescriber about every medication and condition you have.

The coverage overlap we found: Northwest asks about MTC or MEN2 in both its weight-management and OSA criteria, and the current Mid-Atlantic OSA form lists that history among its reasons for noncoverage. This isn't just label fine print. It can also be a question on the coverage review.

We're not going to reprint the label here or tell you what's safe for you. That's a conversation with a clinician, not an article.

Frequently asked questions

Does every Kaiser plan require prior authorization for Zepbound? No. The process varies by region and plan type. Northwest runs a clinical review, Mid-Atlantic uses a PA form, Georgia publishes review criteria, and California Commercial HMO says it doesn't require PA or step therapy and uses a non-formulary coverage-determination process instead. Your Evidence of Coverage and Kaiser's written decision control your case.

Is Zepbound on the Kaiser formulary? There's no single national answer. Zepbound appears with PA and quantity-limit flags on some Kaiser plan formularies, including Hawaii KPIC Added Choice, Colorado KPIC, and Washington PSHB. Kaiser Northwest treats it as non-formulary. It doesn't appear in the California Commercial HMO formulary effective August 4, 2026. Check your exact region, plan type, plan year, and dosage form.

Can a prior authorization override a weight-loss drug exclusion? Usually not. A prior authorization asks whether you meet the plan's criteria. A benefit exclusion means the plan doesn't include that category. First find out which one you're actually facing — the written decision should say.

Does Kaiser make you try Wegovy or Ozempic first? In several public criteria sets, yes. Kaiser Northwest requires at least six months of semaglutide after two failed oral trials, unless the separate exception rules apply. Current Mid-Atlantic requires three months of semaglutide for every weight-management BMI group. Georgia requires you to clear at least two oral options and then at least four months of high-dose or maximum-tolerated semaglutide through failure, intolerance, or contraindication. The duration and surrounding requirements differ by plan.

I tried phentermine five years ago. Does that count? It may — if the plan accepts the past trial and it's documented in your chart with dates, dose, outcome, and a reason you stopped. Bring it up explicitly at your appointment. Kaiser Northwest defines an adequate trial as three months.

What if the side effects were mild but really annoying? Kaiser Northwest's document excludes reactions that are expected, mild, resolve with continued treatment, and don't require stopping the medication. Mild nausea that settled down may not clear the bar. A reaction that made you stop the drug is a different record.

Does prediabetes count as a qualifying condition? At Kaiser Northwest, yes — prediabetes is on the list of conditions that can open the BMI 27 pathway. Other Kaiser plans use different lists and thresholds.

Can my regular outside doctor submit the request? It depends on the plan. Georgia limits the route to listed Kaiser-affiliated prescribers. Mid-Atlantic requires its referral or specialist path. California Commercial HMO allows the member, representative, or a prescriber to start a coverage determination, but the medical support still has to be supplied. Confirm the rule before anyone spends time assembling a packet.

Does having a Zepbound prescription mean Kaiser will pay for it? No. A prescription means a clinician ordered it. Coverage still depends on your drug benefit, formulary, authorization or exception, dosage form, pharmacy channel, and cost share.

How long does Kaiser take to decide? California Commercial HMO publishes 72 hours for a standard coverage determination and 24 hours for an urgent one, with the clock starting when the prescriber submits the supporting statement. The other public regional documents reviewed here don't give one shared Kaiser-wide number. Ask for the expected window and get a reference number.

Kaiser said no prior authorization is needed, but the pharmacy price is huge. What happened? That's usually a formulary, tier, deductible, coinsurance, dosage-form, pharmacy-channel, quantity-limit, or benefit issue rather than a missing authorization. Ask the pharmacy for the exact claim message or code.

Does Medi-Cal through Kaiser cover Zepbound? California's Medi-Cal pharmacy benefit is run by Medi-Cal Rx, not Kaiser's ordinary commercial formulary. Starting January 1, 2026, drugs used only for weight loss are generally excluded for adults, with an EPSDT path for members under 21. Zepbound for the FDA-approved OSA indication may still be reviewed case by case with prior authorization. More: what GLP-1 does Kaiser cover.

Can I use the Lilly savings card with Kaiser? A Kaiser commercial claim may qualify if your prescribed Zepbound form and coverage meet Lilly's terms. The current $25 offer is for eligible commercially insured adults whose plan covers the single-dose pen; other form and coverage situations use different terms. Kaiser Medicare, Medi-Cal, TRICARE, and other government-program coverage doesn't qualify under the current terms. Check Lilly's current terms before counting on it.

Is compounded tirzepatide an option through Kaiser? We found no published Kaiser coverage path for compounded tirzepatide in the sources reviewed. Compounded medications aren't FDA-approved finished drugs and shouldn't be presented as the same product as Zepbound.

What happens when my approval expires? You'll need a continuation request with the measurements and response your plan requires. Northwest asks for 5% loss achieved and maintained. Georgia uses office weights and its 8%-by-six-month or 15%-by-twelve-month checkpoints. Mid-Atlantic uses different weight and OSA renewal tests. Save your baseline from day one.

Your next step, depending on where you landed

If your plan covers weight-loss drugs: bring the trial history, book the appointment, and ask the two specific questions instead of one vague one. You have a real path.

If your plan doesn't cover them: you're looking at open enrollment, a plan-sponsor rider, another plan, or a cash path. LillyDirect at $299–$449 is the lower-cost cash option listed here if you already have a prescriber. Ro adds a membership but includes an outside telehealth care path.

If you're not sure yet: make the five-minute phone call. Use the script. Everything else on this page depends on that one answer.

If you were denied: find out which kind of “no” you got before you file anything. The wrong door costs time.

How this page was made

We built this page because one Kaiser region's rule gets repeated online as though it applies to the whole country — and that error costs people months.

So we opened the documents. Kaiser Northwest's Zepbound criteria. Kaiser Georgia's 577-page review manual. Kaiser Mid-Atlantic's current Commercial, Exchange, and FEHB form and its separate Maryland HealthChoice form. Kaiser's current California Commercial HMO formulary. The Hawaii, Colorado KPIC, and Washington PSHB formularies. We read the FDA-approved Zepbound and Mounjaro labeling, the current Medi-Cal drug list, CMS Bridge rules, Lilly pricing and savings terms, Ro pricing, and California's current appeal form. Then we labeled every row in our table by how complete the public evidence actually is, so a gap in Kaiser's publishing never gets mistaken for a coverage decision.

Where we couldn't confirm something, we said so on the page. Where a free path beats our affiliate offer, we said that too.

Coverage rules change. Some formularies update monthly, while criteria documents carry their own revision and effective dates. We re-check them and update the verification date at the top only when we've actually done the work.

By The RX Index Research Team. Independent guidance for choosing your GLP-1 path.

Primary sources

• Kaiser Permanente Northwest Criteria for Coverage — tirzepatide (Zepbound), revised 6/11/2026
• Kaiser Permanente Georgia Prior Authorization Medications — Criteria for Use, effective 7/8/2026
• Kaiser Permanente Mid-Atlantic Tirzepatide Products PA form, effective 8/4/2026
• Kaiser Permanente Maryland HealthChoice Zepbound PA form, effective 6/3/2025
• Kaiser Permanente California Commercial HMO Formulary, effective 8/4/2026
• Kaiser Permanente Hawaii formulary page
• Hawaii KPIC Added Choice formulary, effective 7/1/2026
• Colorado KPIC PPO/POS formulary, effective 7/1/2026
• Washington PSHB formulary, effective 8/1/2026
• FDA-approved Zepbound Prescribing Information, revised 4/2026
• FDA-approved Mounjaro Prescribing Information
• Medi-Cal Rx Contract Drugs List
• California DMHC IMR Application/Complaint Form, revised 9/2025
• LillyDirect Zepbound self-pay pricing
• Zepbound savings terms
• CMS Medicare GLP-1 Bridge
• CMS Medicare GLP-1 Bridge information for providers
• Ro Body pricing

Still not sure which GLP-1 program is right for you? Take our free matching quiz.

→ Find My GLP-1 Path